Cell>Point is pursuing an
aggressive domestic and international patent protection program for each of
the licensed technologies. The Company's product development and clinical
trial scheduling is geared toward preserving as much of the remaining patent
life for each commercialized product as possible. In every case, the owner
of the patent (domestic or international) is the Board of Regents of The
University of TexasM.D.AndersonCancerCenter.Cell>Point has full patent
rights for life of patent.
The following is the patent
issuance and application status of each of the technology platforms.
1. Initial EC Technology
U.S. patent
issued (US 6,692,724
B1)
2. Second EC Technology
U.S. patent
issued (US 7,067,111)
3. Third EC Technology
U.S. patent application
approved and
awaiting issuance (App. No. 10/672,763)
4. Fourth EC Technology
U.S. patent
approved and
awaiting issuance (App. No. 10/672,142)
5. Fifth EC Technology
U.S. patent application
under examination
(App. No. 11/405/334)
6. Sixth EC Technology
U.S. patent application
under examination
(App. No. 10/732,919)
7. First Australia EC
Technology patent issued (2001275210)
8. First China EC
Technology patent issued (ZL 01811605.1)
9. All remaining
domestic and international
EC Technology patent
applications are in various
stages of review.
10. In-Situ Hydrogel U.S.
patent application approved
and awaiting
issuance (App. No. 10/024/678).
11. All international
In-Situ Hydrogel patent
applications are
pending and in various stages of review.
12. Beta Cell Technology
U.S. patent
application is under
review (App. No. 10/942,615)
13. Beta Cell Technology
international
applications are
under review.
14. Dual Agent Technology
U.S. patent
application under
review (App. No. 11/326,117)
15. N4 Technology U.S.
provisional patent
application filed
September 2006
(App. No.
60/745,148)
16. N4 Technology
international PCT
Patent application
filed September
r & d
